EP1335707A4 - Nouvelles formulations de carvedilol - Google Patents

Nouvelles formulations de carvedilol

Info

Publication number
EP1335707A4
EP1335707A4 EP01273804A EP01273804A EP1335707A4 EP 1335707 A4 EP1335707 A4 EP 1335707A4 EP 01273804 A EP01273804 A EP 01273804A EP 01273804 A EP01273804 A EP 01273804A EP 1335707 A4 EP1335707 A4 EP 1335707A4
Authority
EP
European Patent Office
Prior art keywords
carvedilol
novel formulations
formulations
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01273804A
Other languages
German (de)
English (en)
Other versions
EP1335707A2 (fr
Inventor
Vlassios Andronis
Kimberly A Lamey
Choon K Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1335707A2 publication Critical patent/EP1335707A2/fr
Publication of EP1335707A4 publication Critical patent/EP1335707A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP01273804A 2000-10-24 2001-10-23 Nouvelles formulations de carvedilol Withdrawn EP1335707A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24291100P 2000-10-24 2000-10-24
US242911P 2000-10-24
PCT/US2001/050872 WO2002065834A2 (fr) 2000-10-24 2001-10-23 Nouvelles formulations de carvedilol

Publications (2)

Publication Number Publication Date
EP1335707A2 EP1335707A2 (fr) 2003-08-20
EP1335707A4 true EP1335707A4 (fr) 2005-07-06

Family

ID=22916614

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01273804A Withdrawn EP1335707A4 (fr) 2000-10-24 2001-10-23 Nouvelles formulations de carvedilol

Country Status (5)

Country Link
EP (1) EP1335707A4 (fr)
JP (1) JP2004518734A (fr)
AU (1) AU2001297631A1 (fr)
CA (1) CA2426811A1 (fr)
WO (1) WO2002065834A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69917618T2 (de) 1998-04-03 2005-06-23 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
IN191028B (fr) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
WO2003024430A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
WO2003024429A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme de liberation a base de polymere
WO2003024426A1 (fr) * 2001-09-21 2003-03-27 Egalet A/S Dispersions solides a liberation controlee
WO2004041252A1 (fr) 2002-11-08 2004-05-21 Egalet A/S Compositions de carvedilol a liberation commandee
EP2301526B1 (fr) 2003-03-26 2016-03-23 Egalet Ltd. Système de libération contrôlée de morphine
DK1610768T3 (da) 2003-03-26 2008-09-22 Egalet As Matrikskompositioner til styret afgivelse af lægemiddelsubstanser
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
JP5042041B2 (ja) 2005-02-25 2012-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 心筋症及び心臓病を処置及び予防するための組成物及び方法
HU227490B1 (en) * 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
CN101534843A (zh) 2006-08-01 2009-09-16 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
HU227881B1 (en) * 2007-02-23 2012-05-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
WO2008114276A1 (fr) * 2007-03-16 2008-09-25 Lupin Limited Nouvelle composition orale de carvédilol à libération contrôlée
US8372387B2 (en) 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
WO2010089132A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Composition à libération immédiate résistant à une maltraitance par prise d'alcool
WO2010149169A2 (fr) 2009-06-24 2010-12-29 Egalet A/S Formulations à libération contrôlée
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816036A1 (de) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
WO2000000179A1 (fr) * 1998-06-27 2000-01-06 Won Jin Biopharma Co., Ltd. Preparation a dispersion solide d'un medicament faiblement hydrosoluble contenant de l'huile, un acide gras ou leurs melanges
WO2000004902A1 (fr) * 1998-07-23 2000-02-03 Roche Diagnostics Gmbh Solution pour injection de carvedilol stabilise
WO2000032174A2 (fr) * 1998-11-27 2000-06-08 F. Hoffmann-La Roche Ag Specialite pharmaceutique combinee
WO2001035958A1 (fr) * 1999-11-15 2001-05-25 Smithkline Beecham Corporation Methane-sulfonate de carvedilol
WO2001074356A1 (fr) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Solutions concentrees de carvedilol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
PL335619A1 (en) * 1997-03-11 2000-05-08 Darwin Discovery Ltd Dosage forms including separate parts containing r and s enantiomers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816036A1 (de) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
WO2000000179A1 (fr) * 1998-06-27 2000-01-06 Won Jin Biopharma Co., Ltd. Preparation a dispersion solide d'un medicament faiblement hydrosoluble contenant de l'huile, un acide gras ou leurs melanges
WO2000004902A1 (fr) * 1998-07-23 2000-02-03 Roche Diagnostics Gmbh Solution pour injection de carvedilol stabilise
WO2000032174A2 (fr) * 1998-11-27 2000-06-08 F. Hoffmann-La Roche Ag Specialite pharmaceutique combinee
WO2001035958A1 (fr) * 1999-11-15 2001-05-25 Smithkline Beecham Corporation Methane-sulfonate de carvedilol
WO2001074356A1 (fr) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Solutions concentrees de carvedilol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO02065834A3 *

Also Published As

Publication number Publication date
AU2001297631A1 (en) 2002-09-04
EP1335707A2 (fr) 2003-08-20
AU2001297631A8 (en) 2005-09-15
WO2002065834A8 (fr) 2003-06-26
WO2002065834A2 (fr) 2002-08-29
JP2004518734A (ja) 2004-06-24
CA2426811A1 (fr) 2002-08-29
WO2002065834A3 (fr) 2002-10-03

Similar Documents

Publication Publication Date Title
AU2001297631A8 (en) Novel formulations of carvedilol
HRP20030027A2 (en) Carvedilol
IL142268A0 (en) Ophthalmic formulations
HUP0303732A2 (en) Hsa-free formulations of interferon-beta
GB0015490D0 (en) Novel formulations
AU9473501A (en) Stabilization of solid drug formulations
HUP0201220A3 (en) Adjuvant combination formulations
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
GB0009612D0 (en) Therapeutic formulations
GB9923045D0 (en) New oral formulations
GB0009609D0 (en) Therapeutic compositions
GB0030857D0 (en) Therapeutic compositions
HUP0600589A2 (en) Adjuvant combination formulations
GB0012718D0 (en) Conjugates of aminodrugs
GB0115893D0 (en) Formulations
AU2002341923A1 (en) Novel formulations of carvedilol
GB9911823D0 (en) New vaccine formulations
GB0116403D0 (en) Novel Formulations
GB0022027D0 (en) Disfectant formulations
TW479920U (en) Improvement of socket
GB9909079D0 (en) Novel formulations
GB9909080D0 (en) Novel formulations
NZ513664A (en) Long acting formulations
GB0107226D0 (en) Formulations
GB0008029D0 (en) New vaccine formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030519

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050523

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/403 B

Ipc: 7A 61K 9/62 B

Ipc: 7A 61K 9/58 B

Ipc: 7A 61K 9/52 B

Ipc: 7A 61K 9/30 B

Ipc: 7A 61K 9/26 B

Ipc: 7A 61K 9/22 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070430